Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

An Evaluation of Operant Behavioural Economics in Functional Communication Training for Severe Problem Behaviour.

Gilroy SP, Ford HL, Boyd RJ, O'Connor JT, Kurtz PF.

Dev Neurorehabil. 2019 Nov;22(8):553-564. doi: 10.1080/17518423.2019.1646342. Epub 2019 Jul 25.

PMID:
31342839
2.

Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.

Anantharajan J, Zhou H, Zhang L, Hotz T, Vincent MY, Blevins MA, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Baburajendran N, Lin G, Hung AW, Joy J, Patnaik S, Marugan J, Rudra P, Ghosh D, Hill J, Keller TH, Zhao R, Ford HL, Kang C.

Mol Cancer Ther. 2019 Sep;18(9):1484-1496. doi: 10.1158/1535-7163.MCT-18-1239. Epub 2019 Jul 8.

PMID:
31285279
3.

Managing the (In)visibility of Chronic Illness at Work: Dialogism, Parody, and Reported Speech.

Thompson L, Ford HL, Stroud A, Madill A.

Qual Health Res. 2019 Jul;29(8):1213-1226. doi: 10.1177/1049732319825843. Epub 2019 Feb 9.

4.

SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program.

Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL.

Cancer Res. 2019 Feb 15;79(4):720-734. doi: 10.1158/0008-5472.CAN-18-1791. Epub 2019 Jan 3.

PMID:
30606720
5.

Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.

Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL.

Nat Commun. 2018 Nov 12;9(1):4720. doi: 10.1038/s41467-018-07168-z.

6.

Use of coping strategies in multiple sclerosis: Association with demographic and disease-related characteristics.

Holland DP, Schlüter DK, Young CA, Mills RJ, Rog DJ, Ford HL, Orchard K; TONiC study group.

Mult Scler Relat Disord. 2019 Jan;27:214-222. doi: 10.1016/j.msard.2018.10.016. Epub 2018 Oct 22.

PMID:
30412819
7.

Author Correction: Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression.

Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL.

Nat Commun. 2018 Sep 17;9(1):3830. doi: 10.1038/s41467-018-06265-3.

8.

Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL.

J Clin Invest. 2018 Jun 1;128(6):2535-2550. doi: 10.1172/JCI96784. Epub 2018 May 14.

9.

Gender inequity in speaking opportunities at the American Geophysical Union Fall Meeting.

Ford HL, Brick C, Blaufuss K, Dekens PS.

Nat Commun. 2018 Apr 24;9(1):1358. doi: 10.1038/s41467-018-03809-5.

10.

The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.

Guarnieri AL, Towers CG, Drasin DJ, Oliphant MUJ, Andrysik Z, Hotz TJ, Vartuli RL, Linklater ES, Pandey A, Khanal S, Espinosa JM, Ford HL.

Oncogene. 2018 Jul;37(28):3879-3893. doi: 10.1038/s41388-018-0239-7. Epub 2018 Apr 17.

11.

Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression.

Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL.

Nat Commun. 2018 Mar 13;9(1):1047. doi: 10.1038/s41467-018-03327-4. Erratum in: Nat Commun. 2018 Sep 17;9(1):3830.

12.

Psychological determinants of job retention in multiple sclerosis.

Ford HL, Wicks CR, Stroud A, Tennant A.

Mult Scler. 2019 Mar;25(3):419-426. doi: 10.1177/1352458518754362. Epub 2018 Jan 24.

PMID:
29363395
13.

A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.

Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford HL, Marti J, Pavitt SH, Schmierer K, Manzano A.

Patient. 2018 Aug;11(4):391-402. doi: 10.1007/s40271-017-0296-y.

14.

The Eya phosphatase: Its unique role in cancer.

Zhou H, Zhang L, Vartuli RL, Ford HL, Zhao R.

Int J Biochem Cell Biol. 2018 Mar;96:165-170. doi: 10.1016/j.biocel.2017.09.001. Epub 2017 Sep 5. Review.

15.

Unusual case of bilateral hand weakness.

Datta S, Cosgrove J, Alam T, Ford HL.

Pract Neurol. 2017 Dec;17(6):479-481. doi: 10.1136/practneurol-2017-001640. Epub 2017 Aug 17.

PMID:
28819047
16.

EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.

Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL.

Nat Commun. 2017 Jun 12;8:15773. doi: 10.1038/ncomms15773. Erratum in: Nat Commun. 2018 Nov 12;9(1):4720.

17.

Negative regulation of endothelin signaling by SIX1 is required for proper maxillary development.

Tavares ALP, Cox TC, Maxson RM, Ford HL, Clouthier DE.

Development. 2017 Jun 1;144(11):2021-2031. doi: 10.1242/dev.145144. Epub 2017 Apr 28.

18.

Lesson of the month 2: Transient reversible amnesia in multiple sclerosis.

Shanmugarajah PD, Alty J, Lily O, Ford HL.

Clin Med (Lond). 2017 Feb;17(1):88-90. doi: 10.7861/clinmedicine.17-1-88.

19.

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL.

Mol Cancer Res. 2017 Apr;15(4):382-394. doi: 10.1158/1541-7786.MCR-16-0234. Epub 2017 Jan 20.

20.

CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming.

Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, D'Alessandro A, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ.

Oncotarget. 2017 Jan 24;8(4):6742-6762. doi: 10.18632/oncotarget.14272.

21.

Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells.

Thorburn J, Staskiewicz L, Goodall ML, Dimberg L, Frankel AE, Ford HL, Thorburn A.

Mol Pharmacol. 2017 Jan;91(1):58-64. Epub 2016 Nov 9.

22.

Multiple sclerosis and employment: Associations of psychological factors and work instability.

Wicks CR, Ward K, Stroud A, Tennant A, Ford HL.

J Rehabil Med. 2016 Oct 12;48(9):799-805. doi: 10.2340/16501977-2142.

23.

Clonal cooperativity in heterogenous cancers.

Zhou H, Neelakantan D, Ford HL.

Semin Cell Dev Biol. 2017 Apr;64:79-89. doi: 10.1016/j.semcdb.2016.08.028. Epub 2016 Aug 28. Review.

24.

A tale of two ends.

Towers CG, Ford HL.

Cell Cycle. 2016 Jun 17;15(12):1523-4. doi: 10.1080/15384101.2016.1171652. Epub 2016 Apr 21. No abstract available.

25.

Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.

Vinjam MR, Shanmugarajah P, Ford HL.

J Neurol. 2016 May;263(5):1017-1018. doi: 10.1007/s00415-016-8078-3. Epub 2016 Mar 5. No abstract available.

PMID:
26946498
26.

The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.

Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL.

Nat Commun. 2015 Dec 21;6:10077. doi: 10.1038/ncomms10077.

27.

A rehabilitation training partnership in Madagascar.

Andrianabela S, Hariharan R, Ford HL, Chamberlain MA.

J Rehabil Med. 2015 Sep;47(8):682-7. doi: 10.2340/16501977-1997.

28.

TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.

Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL.

Cancer Res. 2015 May 1;75(9):1908-21. doi: 10.1158/0008-5472.CAN-14-2394. Epub 2015 Feb 25.

29.

Reduced El Niño-Southern Oscillation during the Last Glacial Maximum.

Ford HL, Ravelo AC, Polissar PJ.

Science. 2015 Jan 16;347(6219):255-8. doi: 10.1126/science.1258437.

30.

The SIX1-EYA transcriptional complex as a therapeutic target in cancer.

Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL.

Expert Opin Ther Targets. 2015 Feb;19(2):213-25. doi: 10.1517/14728222.2014.978860. Epub 2015 Jan 2. Review.

31.

Comment on "A 12-million-year temperature history of the tropical Pacific Ocean".

Ravelo AC, Lawrence KT, Fedorov A, Ford HL.

Science. 2014 Dec 19;346(6216):1467. doi: 10.1126/science.1257618.

PMID:
25525238
32.

Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Neelakantan D, Drasin DJ, Ford HL.

Cell Adh Migr. 2015;9(4):265-76. doi: 10.4161/19336918.2014.972761. Epub 2014 Oct 16. Review.

33.

Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.

Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL.

Breast Cancer Res. 2014 Oct 30;16(5):462. doi: 10.1186/s13058-014-0462-2.

34.

Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression.

Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello JC, Tan AC, Ford HL.

Cancer Res. 2014 Dec 15;74(24):7357-70. doi: 10.1158/0008-5472.CAN-14-0666. Epub 2014 Oct 27.

35.

Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.

Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, Southall N, Reigan P, Marugan J, Ford HL, Zhao R.

J Biol Chem. 2014 Jun 6;289(23):16349-61. doi: 10.1074/jbc.M114.566729. Epub 2014 Apr 22.

36.

MicroRNA-30a regulates zebrafish myogenesis through targeting the transcription factor Six1.

O'Brien JH, Hernandez-Lagunas L, Artinger KB, Ford HL.

J Cell Sci. 2014 May 15;127(Pt 10):2291-301. doi: 10.1242/jcs.143677. Epub 2014 Mar 14.

37.

CDK6 binds and promotes the degradation of the EYA2 protein.

Kohrt D, Crary J, Zimmer M, Patrick AN, Ford HL, Hinds PW, Grossel MJ.

Cell Cycle. 2014;13(1):62-71. doi: 10.4161/cc.26755. Epub 2013 Oct 12.

38.

Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.

Cieply B, Farris J, Denvir J, Ford HL, Frisch SM.

Cancer Res. 2013 Oct 15;73(20):6299-309. doi: 10.1158/0008-5472.CAN-12-4082. Epub 2013 Aug 13.

39.

Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case report.

Cosgrove J, Alli S, Ramadan H, Ford HL.

Mult Scler. 2014 Jan;20(1):120-2. doi: 10.1177/1352458513495939. Epub 2013 Jul 11.

PMID:
23846353
40.

Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes.

Auvergne RM, Sim FJ, Wang S, Chandler-Militello D, Burch J, Al Fanek Y, Davis D, Benraiss A, Walter K, Achanta P, Johnson M, Quinones-Hinojosa A, Natesan S, Ford HL, Goldman SA.

Cell Rep. 2013 Jun 27;3(6):2127-41. doi: 10.1016/j.celrep.2013.04.035. Epub 2013 May 30. Erratum in: Cell Rep. 2013 Jul 25;4(2):402.

41.

Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome.

Patrick AN, Cabrera JH, Smith AL, Chen XS, Ford HL, Zhao R.

Nat Struct Mol Biol. 2013 Apr;20(4):447-53. doi: 10.1038/nsmb.2505. Epub 2013 Feb 24.

42.

Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.

Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, Ford HL, Zheng W, Zhao R.

J Biomol Screen. 2013 Jan;18(1):85-96. doi: 10.1177/1087057112453936. Epub 2012 Jul 20.

43.

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL.

Breast Cancer Res. 2012 Jul 5;14(4):R100. doi: 10.1186/bcr3219.

44.

EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL.

Mol Cancer Res. 2012 Aug;10(8):1098-108. doi: 10.1158/1541-7786.MCR-12-0086. Epub 2012 Jun 20.

45.

Molecular pathways: targeting the TGF-β pathway for cancer therapy.

Smith AL, Robin TP, Ford HL.

Clin Cancer Res. 2012 Sep 1;18(17):4514-21. doi: 10.1158/1078-0432.CCR-11-3224. Epub 2012 Jun 18. Review.

46.

Late Miocene decoupling of oceanic warmth and atmospheric carbon dioxide forcing.

LaRiviere JP, Ravelo AC, Crimmins A, Dekens PS, Ford HL, Lyle M, Wara MW.

Nature. 2012 Jun 6;486(7401):97-100. doi: 10.1038/nature11200.

PMID:
22678287
47.

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.

Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL.

Oncogene. 2013 Mar 14;32(11):1341-50. doi: 10.1038/onc.2012.164. Epub 2012 May 14. Review.

48.

SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer.

Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL.

J Clin Invest. 2012 May;122(5):1895-906. doi: 10.1172/JCI59858. Epub 2012 Apr 2.

49.

Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.

Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K.

Gynecol Oncol. 2012 May;125(2):451-7. doi: 10.1016/j.ygyno.2012.02.007. Epub 2012 Feb 12.

50.

The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.

Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL.

Oncogene. 2012 Dec 13;31(50):5162-71. doi: 10.1038/onc.2012.11. Epub 2012 Jan 30.

Supplemental Content

Support Center